These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28295486)

  • 1. Estimating efficacy in trials with selective crossover.
    Brentnall AR; Sasieni P; Cuzick J
    Stat Med; 2017 Jul; 36(15):2333-2346. PubMed ID: 28295486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
    Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
    Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update of the BIG 1-98 Trial: where do we stand?
    Joerger M; Thürlimann B
    Breast; 2009 Oct; 18 Suppl 3():S78-82. PubMed ID: 19914548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.
    Mouridsen H; Gershanovich M; Sun Y; Perez-Carrion R; Boni C; Monnier A; Apffelstaedt J; Smith R; Sleeboom HP; Jaenicke F; Pluzanska A; Dank M; Becquart D; Bapsy PP; Salminen E; Snyder R; Chaudri-Ross H; Lang R; Wyld P; Bhatnagar A
    J Clin Oncol; 2003 Jun; 21(11):2101-9. PubMed ID: 12775735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.
    Lazar AA; Bonetti M; Cole BF; Yip WK; Gelber RD
    Clin Trials; 2016 Apr; 13(2):169-79. PubMed ID: 26493094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On an enhanced rank-preserving structural failure time model to handle treatment switch, crossover, and dropout.
    Li L; Tang S; Jiang L
    Stat Med; 2017 May; 36(10):1532-1547. PubMed ID: 28110508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.
    Jin H; Tu D; Zhao N; Shepherd LE; Goss PE
    J Clin Oncol; 2012 Mar; 30(7):718-21. PubMed ID: 22042967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
    Colleoni M; Giobbie-Hurder A; Regan MM; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Láng I; Smith I; Chirgwin J; Pienkowski T; Wardley A; Price KN; Gelber RD; Coates AS; Goldhirsch A
    J Clin Oncol; 2011 Mar; 29(9):1117-24. PubMed ID: 21321298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporating prognostic factors into causal estimators: a comparison of methods for randomised controlled trials with a time-to-event outcome.
    Hampson LV; Metcalfe C
    Stat Med; 2012 Nov; 31(26):3073-88. PubMed ID: 22714785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL
    J Natl Cancer Inst; 2005 Sep; 97(17):1262-71. PubMed ID: 16145047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2011; 16(12):1762-70. PubMed ID: 22089970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer.
    Piccart MJ; Cardoso F; Atalay G
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S52-4. PubMed ID: 12409074
    [No Abstract]   [Full Text] [Related]  

  • 16. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
    Ewertz M; Gray KP; Regan MM; Ejlertsen B; Price KN; Thürlimann B; Bonnefoi H; Forbes JF; Paridaens RJ; Rabaglio M; Gelber RD; Colleoni M; Láng I; Smith IE; Coates AS; Goldhirsch A; Mouridsen HT
    J Clin Oncol; 2012 Nov; 30(32):3967-75. PubMed ID: 23045588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    DeGrendele H
    Clin Breast Cancer; 2003 Dec; 4(5):311-2. PubMed ID: 14715105
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.